Clinical trials
Terminated trials in Switzerland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
931 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 7 |
| 2002 | 6 |
| 2003 | 10 |
| 2004 | 11 |
| 2005 | 26 |
| 2006 | 28 |
| 2007 | 23 |
| 2008 | 34 |
| 2009 | 35 |
| 2010 | 45 |
| 2011 | 35 |
| 2012 | 49 |
| 2013 | 48 |
| 2014 | 49 |
| 2015 | 60 |
| 2016 | 57 |
| 2017 | 68 |
| 2018 | 64 |
| 2019 | 57 |
| 2020 | 70 |
| 2021 | 50 |
| 2022 | 47 |
| 2023 | 31 |
| 2024 | 8 |
| 2025 | 7 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 931 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Insel Gruppe AG, University Hospital Bern | 73 |
| Novartis Pharmaceuticals | 55 |
| University of Zurich | 55 |
| University Hospital, Basel, Switzerland | 42 |
| Hoffmann-La Roche | 28 |
| Swiss Cancer Institute | 27 |
| University Hospital, Geneva | 26 |
| Pfizer | 21 |
| Amgen | 17 |
| Centre Hospitalier Universitaire Vaudois | 14 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stroke | 30 |
| Neoplasms | 26 |
| Carcinoma, Non-Small-Cell Lung | 25 |
| Breast Neoplasms | 19 |
| Crohn Disease | 19 |
| Melanoma | 18 |
| Cardiovascular Diseases | 17 |
| Alzheimer Disease | 16 |
| Heart Failure | 15 |
| COVID-19 | 13 |
Trials
Showing 51 to 75 of 931. Each trial links to its page on Pharma Observatory.
831 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.